

CMS Chronic Condition Data Warehouse (CCW) Medicare*
2017 Top 10 Classes of Part D Prescription Drugs by Utilization and Cost (in Millions)

Table F.4

Number of Beneficiaries Enrolled in Part D*	45,235,350
Total Prescription Drug Events (fills)	1,498,436,464
Total Drug costs† (gross costs; rounded to millions)	\$154,833

Top 10 drugs (broad therapeutic class‡) by use

Number of prescription fills (and % PDEs) for:	Rank		Percent
Cardiovascular drugs	1	461,268,764	30.8%
Central nervous system agents	2	384,982,200	25.7%
Hormones and synthetic substitutes	3	185,488,587	12.4%
Autonomic drugs	4	178,322,397	11.9%
Electrolytic, caloric, and water balance	5	107,973,854	7.2%
Gastrointestinal drugs	6	95,391,293	6.4%
Anti-infective agents	7	77,240,225	5.2%
Respiratory tract agents	8	66,922,759	4.5%
Eye, Ear, Nose and Throat (EENT) Preps.	9	57,108,674	3.8%
Blood formation, coagulation, and thrombosis	10	46,850,215	3.1%

Top 10 drugs (broad therapeutic class‡) by gross cost

(rounded to millions)

Total cost† (and % gross costs) for:	Rank		Percent
Hormones and synthetic substitutes	1	\$35,613	23.0%
Central nervous system agents	2	\$23,595	15.2%
Miscellaneous therapeutic agents	3	\$20,816	13.4%
Cardiovascular drugs	4	\$16,224	10.5%
Respiratory tract agents	5	\$15,285	9.9%
Anti-neoplastic agents	6	\$15,076	9.7%
Autonomic drugs	7	\$14,477	9.4%
Anti-infective agents	8	\$13,109	8.5%
Gastrointestinal drugs	9	\$9,221	6.0%
Blood formation, coagulation & thrombosis	10	\$8,471	5.5%

Footnotes:

* Includes Medicare beneficiaries who were eligible for or enrolled in Medicare Part D on or after January 1, YYYY.

† Total cost is obtained by summing the gross cost of each PDE. These costs do not reflect the savings due to manufacturers' rebates or other price concessions. The costs are not indicative of the full cost to CMS for the Part D program. Dollars are rounded and expressed in millions.

‡ Therapeutic class as defined by AHFS. It is possible that a drug may be included in more than one class.

Report Release Date: 05/04/2019

This material was developed under a contract with the Centers for Medicare & Medicaid Services (CMS).

CMS Chronic Condition Data Warehouse (CCW) Medicare*
2016 Top 10 Classes of Part D Prescription Drugs by Utilization and Cost (in Millions)

Table F.4

Number of Beneficiaries Enrolled in Part D*	43,587,021
Total Prescription Drug Events (fills)	1,484,005,937
Total Drug costs† (gross costs; rounded to millions)	\$146,144

Top 10 drugs (broad therapeutic class‡) by use

Number of prescription fills (and % PDEs) for:	Rank		Percent
Cardiovascular drugs	1	464,896,844	31.3%
Central nervous system agents	2	382,352,692	25.8%
Hormones and synthetic substitutes	3	177,695,347	12.0%
Autonomic drugs	4	174,820,297	11.8%
Electrolytic, caloric, and water balance	5	110,041,532	7.4%
Gastrointestinal drugs	6	94,851,925	6.4%
Anti-infective agents	7	74,144,886	5.0%
Respiratory tract agents	8	65,277,276	4.4%
Eye, Ear, Nose and Throat (EENT) Preps.	9	55,587,589	3.7%
Blood formation, coagulation, and thrombosis	10	46,114,665	3.1%

Top 10 drugs (broad therapeutic class‡) by gross cost

(rounded to millions)

Total cost† (and % gross costs) for:	Rank		Percent
Hormones and synthetic substitutes	1	\$30,186	20.7%
Central nervous system agents	2	\$23,416	16.0%
Miscellaneous therapeutic agents	3	\$19,551	13.4%
Cardiovascular drugs	4	\$18,209	12.5%
Anti-infective agents	5	\$14,324	9.8%
Respiratory tract agents	6	\$13,741	9.4%
Autonomic drugs	7	\$13,125	9.0%
Anti-neoplastic agents	8	\$12,577	8.6%
Gastrointestinal drugs	9	\$8,637	5.9%
Blood formation, coagulation & thrombosis	10	\$6,570	4.5%

Footnotes:

* Includes Medicare beneficiaries who were eligible for or enrolled in Medicare Part D on or after January 1, YYYY.

† Total cost is obtained by summing the gross cost of each PDE. These costs do not reflect the savings due to manufacturers' rebates or other price concessions. The costs are not indicative of the full cost to CMS for the Part D program. Dollars are rounded and expressed in millions.

‡ Therapeutic class as defined by AHFS. It is possible that a drug may be included in more than one class.

Report Release Date: 05/04/2019

This material was developed under a contract with the Centers for Medicare & Medicaid Services (CMS).

CMS Chronic Condition Data Warehouse (CCW) Medicare*
2015 Top 10 Classes of Part D Prescription Drugs by Utilization and Cost (in Millions)

Table F.4

Number of Beneficiaries Enrolled in Part D*	41,859,463
Total Prescription Drug Events (fills)	1,450,055,791
Total Drug costs† (gross costs; rounded to millions)	\$137,378

Top 10 drugs (broad therapeutic class‡) by use

Number of prescription fills (and % PDEs) for:	Rank		Percent
Cardiovascular drugs	1	458,104,565	31.6%
Central nervous system agents	2	373,233,096	25.7%
Hormones and synthetic substitutes	3	171,773,348	11.8%
Autonomic drugs	4	166,034,786	11.5%
Electrolytic, caloric, and water balance	5	109,552,608	7.6%
Gastrointestinal drugs	6	92,838,054	6.4%
Anti-infective agents	7	73,232,667	5.1%
Respiratory tract agents	8	63,660,346	4.4%
Eye, Ear, Nose and Throat (EENT) Preps.	9	54,003,398	3.7%
Blood formation, coagulation, and thrombosis	10	44,634,950	3.1%

Top 10 drugs (broad therapeutic class‡) by gross cost

(rounded to millions)

Total cost† (and % gross costs) for:	Rank		Percent
Hormones and synthetic substitutes	1	\$26,620	19.4%
Central nervous system agents	2	\$24,205	17.6%
Cardiovascular drugs	3	\$18,063	13.1%
Miscellaneous therapeutic agents	4	\$16,653	12.1%
Anti-infective agents	5	\$16,202	11.8%
Autonomic drugs	6	\$12,389	9.0%
Respiratory tract agents	7	\$12,124	8.8%
Anti-neoplastic agents	8	\$9,933	7.2%
Gastrointestinal drugs	9	\$8,209	6.0%
Blood formation, coagulation & thrombosis	10	\$5,122	3.7%

Footnotes:

* Includes Medicare beneficiaries who were eligible for or enrolled in Medicare Part D on or after January 1, YYYY.

† Total cost is obtained by summing the gross cost of each PDE. These costs do not reflect the savings due to manufacturers' rebates or other price concessions. The costs are not indicative of the full cost to CMS for the Part D program. Dollars are rounded and expressed in millions.

‡ Therapeutic class as defined by AHFS. It is possible that a drug may be included in more than one class.

Report Release Date: 05/04/2019

This material was developed under a contract with the Centers for Medicare & Medicaid Services (CMS).

CMS Chronic Condition Data Warehouse (CCW) Medicare*
2014 Top 10 Classes of Part D Prescription Drugs by Utilization and Cost (in Millions)

Table F.4

Number of Beneficiaries Enrolled in Part D*	39,995,519
Total Prescription Drug Events (fills)	1,417,056,465
Total Drug costs† (gross costs; rounded to millions)	\$121,460

Top 10 drugs (broad therapeutic class‡) by use

Number of prescription fills (and % PDEs) for:	Rank		Percent
Cardiovascular drugs	1	453,964,606	32.0%
Central nervous system agents	2	365,538,933	25.8%
Hormones and synthetic substitutes	3	165,640,365	11.7%
Autonomic drugs	4	161,182,036	11.4%
Electrolytic, caloric, and water balance	5	109,694,701	7.7%
Gastrointestinal drugs	6	90,396,048	6.4%
Anti-infective agents	7	69,184,284	4.9%
Respiratory tract agents	8	60,943,598	4.3%
Eye, Ear, Nose and Throat (EENT) Preps.	9	51,842,406	3.7%
Miscellaneous therapeutic agents	10	43,737,043	3.1%

Top 10 drugs (broad therapeutic class‡) by gross cost

(rounded to millions)

Total cost† (and % gross costs) for:	Rank		Percent
Central nervous system agents	1	\$24,754	20.4%
Hormones and synthetic substitutes	2	\$22,392	18.4%
Cardiovascular drugs	3	\$18,500	15.2%
Miscellaneous therapeutic agents	4	\$13,612	11.2%
Anti-infective agents	5	\$11,399	9.4%
Autonomic drugs	6	\$11,341	9.3%
Respiratory tract agents	7	\$10,528	8.7%
Gastrointestinal drugs	8	\$7,658	6.3%
Anti-neoplastic agents	9	\$7,434	6.1%
Blood formation, coagulation & thrombosis	10	\$4,191	3.5%

Footnotes:

* Includes Medicare beneficiaries who were eligible for or enrolled in Medicare Part D on or after January 1, YYYY.

† Total cost is obtained by summing the gross cost of each PDE. These costs do not reflect the savings due to manufacturers' rebates or other price concessions. The costs are not indicative of the full cost to CMS for the Part D program. Dollars are rounded and expressed in millions.

‡ Therapeutic class as defined by AHFS. It is possible that a drug may be included in more than one class.

Report Release Date: 05/04/2019

This material was developed under a contract with the Centers for Medicare & Medicaid Services (CMS).

CMS Chronic Condition Data Warehouse (CCW) Medicare*
2013 Top 10 Classes of Part D Prescription Drugs by Utilization and Cost (in Millions)

Table F.4

Number of Beneficiaries Enrolled in Part D*	37,839,618
Total Prescription Drug Events (fills)	1,371,343,181
Total Drug costs† (gross costs; rounded to millions)	\$103,700

Top 10 drugs (broad therapeutic class‡) by use

Number of prescription fills (and % PDEs) for:	Rank		Percent
Cardiovascular drugs	1	447,058,881	32.6%
Central nervous system agents	2	350,212,001	25.5%
Hormones and synthetic substitutes	3	159,283,539	11.6%
Autonomic drugs	4	157,151,821	11.5%
Electrolytic, caloric, and water balance	5	108,817,595	7.9%
Gastrointestinal drugs	6	86,233,033	6.3%
Anti-infective agents	7	66,211,345	4.8%
Respiratory tract agents	8	57,993,499	4.2%
Eye, Ear, Nose and Throat (EENT) Preps.	9	48,496,797	3.5%
Blood formation, coagulation & thrombosis	10	42,706,292	3.1%

Top 10 drugs (broad therapeutic class‡) by gross cost

(rounded to millions)

Total cost† (and % gross costs) for:	Rank		Percent
Central nervous system agents	1	\$22,872	22.1%
Hormones and synthetic substitutes	2	\$18,239	17.6%
Cardiovascular drugs	3	\$18,216	17.6%
Autonomic drugs	4	\$10,435	10.1%
Miscellaneous therapeutic agents	5	\$10,139	9.8%
Respiratory tract agents	6	\$9,208	8.9%
Gastrointestinal drugs	7	\$6,900	6.7%
Anti-infective agents	8	\$6,385	6.2%
Anti-neoplastic agents	9	\$5,435	5.2%
Blood formation, coagulation & thrombosis	10	\$3,649	3.5%

Footnotes:

* Includes Medicare beneficiaries who were eligible for or enrolled in Medicare Part D on or after January 1, YYYY.

† Total cost is obtained by summing the gross cost of each PDE. These costs do not reflect the savings due to manufacturers' rebates or other price concessions. The costs are not indicative of the full cost to CMS for the Part D program. Dollars are rounded and expressed in millions.

‡ Therapeutic class as defined by AHFS. It is possible that a drug may be included in more than one class.

Report Release Date: 05/04/2019

This material was developed under a contract with the Centers for Medicare & Medicaid Services (CMS).

CMS Chronic Condition Data Warehouse (CCW) Medicare*
2012 Top 10 Classes of Part D Prescription Drugs by Utilization and Cost (in Millions)

Table F.4

Number of Beneficiaries Enrolled in Part D*	33,789,486
Total Prescription Drug Events (fills)	1,216,491,345
Total Drug costs† (gross costs; rounded to millions)	\$89,831

Top 10 drugs (broad therapeutic class‡) by use

Number of prescription fills (and % PDEs) for:	Rank		Percent
Cardiovascular drugs	1	411,121,884	33.8%
Central nervous system agents	2	286,654,387	23.6%
Hormones and synthetic substitutes	3	144,565,417	11.9%
Autonomic drugs	4	144,033,509	11.8%
Electrolytic, caloric, and water balance	5	100,662,487	8.3%
Gastrointestinal drugs	6	76,800,166	6.3%
Anti-infective agents	7	59,589,597	4.9%
Respiratory tract agents	8	52,036,246	4.3%
Eye, Ear, Nose and Throat (EENT) Preps.	9	42,532,454	3.5%
Blood formation, coagulation & thrombosis	10	39,631,692	3.3%

Top 10 drugs (broad therapeutic class‡) by gross cost

(rounded to millions)

Total cost† (and % gross costs) for:	Rank		Percent
Central nervous system agents	1	\$20,653	23.0%
Cardiovascular drugs	2	\$17,173	19.1%
Hormones and synthetic substitutes	3	\$14,210	15.8%
Autonomic drugs	4	\$8,742	9.7%
Respiratory tract agents	5	\$8,144	9.1%
Miscellaneous therapeutic agents	6	\$7,113	7.9%
Anti-infective agents	7	\$5,677	6.3%
Gastrointestinal drugs	8	\$4,906	5.5%
Blood formation, coagulation & thrombosis	9	\$4,392	4.9%
Anti-neoplastic agents	10	\$3,518	3.9%

Footnotes:

* Includes Medicare beneficiaries who were eligible for or enrolled in Medicare Part D on or after January 1, YYYY.

† Total cost is obtained by summing the gross cost of each PDE. These costs do not reflect the savings due to manufacturers' rebates or other price concessions. The costs are not indicative of the full cost to CMS for the Part D program. Dollars are rounded and expressed in millions.

‡ Therapeutic class as defined by AHFS. It is possible that a drug may be included in more than one class.

Report Release Date: 05/04/2019

This material was developed under a contract with the Centers for Medicare & Medicaid Services (CMS).

CMS Chronic Condition Data Warehouse (CCW) Medicare*
2011 Top 10 Classes of Part D Prescription Drugs by Utilization and Cost (in Millions)

Table F.4

Number of Beneficiaries Enrolled in Part D*	31,480,779
Total Prescription Drug Events (fills)	1,155,913,341
Total Drug costs† (gross costs; rounded to millions)	\$84,887

Top 10 drugs (broad therapeutic class‡) by use

Number of prescription fills (and % PDEs) for:	Rank		Percent
Cardiovascular drugs	1	395,927,143	34.3%
Central nervous system agents	2	269,680,865	23.3%
Autonomic drugs	3	138,330,169	12.0%
Hormones and synthetic substitutes	4	137,534,721	11.9%
Electrolytic, caloric, and water balance	5	98,657,709	8.5%
Gastrointestinal drugs	6	70,873,938	6.1%
Anti-infective agents	7	55,854,079	4.8%
Respiratory tract agents	8	50,694,821	4.4%
Blood formation, coagulation & thrombosis	9	38,482,901	3.3%
Eye, Ear, Nose and Throat (EENT) Preps.	10	38,002,901	3.3%

Top 10 drugs (broad therapeutic class‡) by gross cost

(rounded to millions)

Total cost† (and % gross costs) for:	Rank		Percent
Central nervous system agents	1	\$20,766	24.5%
Cardiovascular drugs	2	\$16,943	20.0%
Hormones and synthetic substitutes	3	\$12,014	14.2%
Autonomic drugs	4	\$8,468	10.0%
Respiratory tract agents	5	\$7,119	8.4%
Miscellaneous therapeutic agents	6	\$5,850	6.9%
Blood formation, coagulation & thrombosis	7	\$5,431	6.4%
Anti-infective agents	8	\$5,062	6.0%
Gastrointestinal drugs	9	\$4,609	5.4%
Electrolytic, caloric, and water balance	10	\$2,986	3.5%

Footnotes:

* Includes Medicare beneficiaries who were eligible for or enrolled in Medicare Part D on or after January 1, YYYY.

† Total cost is obtained by summing the gross cost of each PDE. These costs do not reflect the savings due to manufacturers' rebates or other price concessions. The costs are not indicative of the full cost to CMS for the Part D program. Dollars are rounded and expressed in millions.

‡ Therapeutic class as defined by AHFS. It is possible that a drug may be included in more than one class.

Report Release Date: 05/04/2019

This material was developed under a contract with the Centers for Medicare & Medicaid Services (CMS).

CMS Chronic Condition Data Warehouse (CCW) Medicare*
2010 Top 10 Classes of Part D Prescription Drugs by Utilization and Cost (in Millions)

Table F.4

Number of Beneficiaries Enrolled in Part D*	29,745,502
Total Prescription Drug Events (fills)	1,109,910,261
Total Drug costs† (gross costs; rounded to millions)	\$77,624

Top 10 drugs (broad therapeutic class‡) by use

Number of prescription fills (and % PDEs) for:	Rank		Percent
Cardiovascular drugs	1	386,477,034	34.8%
Central nervous system agents	2	253,212,816	22.8%
Autonomic drugs	3	133,131,628	12.0%
Hormones and synthetic substitutes	4	132,675,410	12.0%
Electrolytic, caloric, and water balance	5	97,897,604	8.8%
Gastrointestinal drugs	6	67,058,328	6.0%
Anti-infective agents	7	52,300,045	4.7%
Respiratory tract agents	8	50,472,051	4.5%
Blood formation, coagulation & thrombosis	9	37,238,150	3.4%
Eye, Ear, Nose and Throat (EENT) Preps.	10	33,941,295	3.1%

Top 10 drugs (broad therapeutic class‡) by gross cost

(rounded to millions)

Total cost† (and % gross costs) for:	Rank		Percent
Central nervous system agents	1	\$18,805	24.2%
Cardiovascular drugs	2	\$15,832	20.4%
Hormones and synthetic substitutes	3	\$10,309	13.3%
Autonomic drugs	4	\$8,772	11.3%
Respiratory tract agents	5	\$6,181	8.0%
Gastrointestinal drugs	6	\$4,940	6.4%
Miscellaneous therapeutic agents	7	\$4,875	6.3%
Blood formation, coagulation & thrombosis	8	\$4,555	5.9%
Anti-infective agents	9	\$4,400	5.7%
Electrolytic, caloric, and water balance	10	\$2,752	3.5%

Footnotes:

* Includes Medicare beneficiaries who were eligible for or enrolled in Medicare Part D on or after January 1, YYYY.

† Total cost is obtained by summing the gross cost of each PDE. These costs do not reflect the savings due to manufacturers' rebates or other price concessions. The costs are not indicative of the full cost to CMS for the Part D program. Dollars are rounded and expressed in millions.

‡ Therapeutic class as defined by AHFS. It is possible that a drug may be included in more than one class.

Report Release Date: 05/04/2019

This material was developed under a contract with the Centers for Medicare & Medicaid Services (CMS).

CMS Chronic Condition Data Warehouse (CCW) Medicare*
2009 Top 10 Classes of Part D Prescription Drugs by Utilization and Cost (in Millions)

Table F.4

Number of Beneficiaries Enrolled in Part D*	28,711,977
Total Prescription Drug Events (fills)	1,076,736,665
Total Drug costs† (gross costs; rounded to millions)	\$73,715

Top 10 drugs (broad therapeutic class) by use

Number of prescription fills (and % PDEs) for:	Rank		Percent
Cardiovascular drugs	1	378,720,189	35.2%
Central nervous system agents	2	240,810,468	22.4%
Autonomic drugs	3	128,721,531	12.0%
Hormones and synthetic substitutes	4	128,403,052	11.9%
Electrolytic, caloric, and water balance	5	98,025,250	9.1%
Gastrointestinal drugs	6	65,655,838	6.1%
Anti-infective agents	7	50,401,528	4.7%
Respiratory tract agents	8	48,678,078	4.5%
Blood formation, coagulation & thrombosis	9	36,605,012	3.4%
Eye, Ear, Nose and Throat (EENT) Preps.	10	32,061,118	3.0%

Top 10 drugs (broad therapeutic class) by gross cost (rounded to millions)

Total cost† (and % gross costs) for:	Rank		Percent
Central nervous system agents	1	\$18,168	24.6%
Cardiovascular drugs	2	\$15,329	20.8%
Hormones and synthetic substitutes	3	\$9,227	12.5%
Autonomic drugs	4	\$8,197	11.1%
Respiratory tract agents	5	\$5,460	7.4%
Gastrointestinal drugs	6	\$5,421	7.4%
Miscellaneous therapeutic agents	7	\$4,359	5.9%
Blood formation, coagulation & thrombosis	8	\$4,089	5.5%
Anti-infective agents	9	\$4,078	5.5%
Electrolytic, caloric, and water balance	10	\$2,605	3.5%

Footnotes:

* Includes Medicare beneficiaries who were eligible for or enrolled in Medicare Part D on or after January 1, YYYY.

† Total cost is obtained by summing the gross cost of each PDE. These costs do not reflect the savings due to manufacturers' rebates or other price concessions. The costs are not indicative of the full cost to CMS for the Part D program. Dollars are rounded and expressed in millions.

‡ Therapeutic class as defined by AHFS. It is possible that a drug may be included in more than one class.

Report Release Date: 05/04/2019

This material was developed under a contract with the Centers for Medicare & Medicaid Services (CMS).

CMS Chronic Condition Data Warehouse (CCW) Medicare*
2008 Top 10 Classes of Part D Prescription Drugs by Utilization and Cost (in Millions)

Table F.4

Number of Beneficiaries Enrolled in Part D*	27,530,929
Total Prescription Drug Events (fills)	1,036,673,680
Total Drug costs [†] (gross costs; rounded to millions)	\$68,525

Top 10 drugs (broad therapeutic class[‡]) by use

Number of prescription fills (and % PDEs) for:	Rank		Percent
Cardiovascular drugs	1	369,887,011	35.7%
Central Nervous System agents	2	225,551,617	21.8%
Hormones and Synthetic substitutes	3	123,748,788	11.9%
Electrolytic, caloric, and water balance	4	98,298,945	9.5%
Gastrointestinal drugs	5	61,424,193	5.9%
Autonomic drugs	6	48,524,114	4.7%
Anti-infective agents	7	48,026,015	4.6%
Respiratory tract agents	8	46,898,609	4.5%
Miscellaneous therapeutic agents	9	36,344,519	3.5%
Blood formation, coagulation & thrombosis	10	35,344,959	3.4%

Top 10 drugs (broad therapeutic class[‡]) by gross cost (rounded to millions)

Total cost[†] (and % gross costs) for:	Rank		Percent
Central Nervous System agents	1	\$17,881	26.1%
Cardiovascular drugs	2	\$14,707	21.5%
Hormones and Synthetic substitutes	3	\$7,914	11.5%
Gastrointestinal drugs	4	\$5,087	7.4%
Miscellaneous therapeutic agents	5	\$4,975	7.3%
Autonomic drugs	6	\$4,885	7.1%
Respiratory tract agents	7	\$4,685	6.8%
Anti-infective agents	8	\$3,708	5.4%
Blood formation, coagulation & thrombosis	9	\$3,590	5.2%
Electrolytic, caloric, and water balance	10	\$2,387	3.5%

Footnotes:

* Includes Medicare beneficiaries who were eligible for or enrolled in Medicare Part D on or after January 1, YYYY.

[†] Total cost is obtained by summing the gross cost of each PDE. These costs do not reflect the savings due to manufacturers' rebates or other price concessions. The costs are not indicative of the full cost to CMS for the Part D program. Dollars are rounded and expressed in millions.

[‡] Therapeutic class as defined by AHFS. It is possible that a drug may be included in more than one class.

Report Release Date: 05/04/2019

This material was developed under a contract with the Centers for Medicare & Medicaid Services (CMS).